Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis

Leukemia. 2023 Jul;37(7):1558-1560. doi: 10.1038/s41375-023-01915-y. Epub 2023 May 23.

Authors

Akiva Diamond¹, Long Vu^{2

3}, Wyatt P Bensken^{2

3}, Siran M Koroukian^{2

3}, Paolo F Caimi⁴

Affiliations

¹ Dan L Duncan Comprehensive Cancer Center at Baylor St. Luke's Medical Center, Houston, TX, USA. Akiva.Diamond@BCM.edu.
² Population Cancer Analytics Shared Resource, Case Comprehensive Cancer Center, Cleveland, OH, USA.
³ Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
⁴ Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.

No abstract available

Publication types

Research Support, U.S. Gov't, P.H.S.
Research Support, Non-U.S. Gov't
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chlorambucil* / therapeutic use
Disease-Free Survival
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Medicare
Rituximab / therapeutic use
United States

Substances

Chlorambucil
Rituximab

Grants and funding